Overview
Spherix’s coverage of the plaque psoriasis market focuses on the shift from long standing biologic treatments to alternative mechanisms of action, highlighting in-class competition.
Services Available
Trending market evolution
Plaque Psoriasis (US) - quarterly, n=100
Plaque Psoriasis (EU) - semiannual, n=250
Exploring the patient journey
Biologic/Small Molecule New Starts in PSO (US) - n=1,000 patient charts
Biologic/Small Molecule Switching in PSO (US) - n=1,000 patient charts
Biologic/Small Molecule Switching in PSO (EU) - n=1,250 patient charts
Biologic/Small Molecule Switching in PsA – Dermatology Perspective (US) - n=500 patient charts
Benchmarking new brand performance
Bimekizumab (UCB) in Psoriasis (US)*
*Pending approvals and launch
Gauging impact of disruptive events
Multi-Specialty Impact of COVID-19 (US)